Mechanistically, N6AMT1 acted as a methyltransferase for 6mA formation and repressed the gene expression of key cell cycle inhibitors such as RB1 and TP53, which was also the first study on the regulation and function of 6mA modification in breast cancer progression and prognosis. The gene discussed is HEMK2; the disease is breast cancer.